Coordinated activation of TGF- β and BMP pathways promotes autophagy and limits liver injury after acetaminophen intoxication
TGF- β and BMP signaling promote autophagy after acetaminophen-induced liver injury. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 28, 2022 Category: Science Source Type: news

Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Acetaminophen Linked to Diminished Response to Immunotherapy in Cancer Acetaminophen Linked to Diminished Response to Immunotherapy in Cancer
The commonly used pain killer was strongly associated with a diminished response to immune checkpoint inhibitors in a study of 600 patients with cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Sodium Hidden in Medication: A Tough Pill To Swallow The Sodium Hidden in Medication: A Tough Pill To Swallow
A new study discovered alarming quantities of sodium in some acetaminophen preparations. Should mandatory labeling of medications containing significant quantities of sodium be required?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Growing Number of Young People Are Attempting Suicide by Self-Poisoning
Suicides among young people have been on the rise for a long time. Among 10 to 24 year olds, overall rates of deaths by suicide in the U.S. increased 57% from 2000 to 2018, according to federal data. Now, a new study published in the journal Clinical Toxicology has looked more closely at a particular method of attempted suicide—self-poisoning—and turned up some disturbing results: From 2015 to 2020, suicide attempts by ingesting toxic substances or overdosing on medications soared by 26% among people ages 6 to 19. [time-brightcove not-tgx=”true”] The research, led by Dr. Jennifer Ross, a medical tox...
Source: TIME: Health - June 1, 2022 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized healthscienceclimate Mental Health Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

$3.2M Grant Brings UAMS Overdose Test Closer to Market
The money will fund a final study of the acetaminophen toxicity test before researchers seek FDA approval. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 23, 2022 Category: American Health Source Type: news

Acetaminophen Information
Acetaminophen: FDA encourages the safe use of over-the-counter (OTC) and prescription (Rx) pain medicines. The FDA has taken action to improve the safety of consumers when using acetaminophen. Information for use during pregnancy, in children, and risk of rare skin disease is provided to help consumers make safer choices. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 17, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Label Changes Did Not Cut Accidental Acetaminophen Overdoses Label Changes Did Not Cut Accidental Acetaminophen Overdoses
Although acetaminophen is safe at therapeutic doses, overdose entails a risk for acute liver failure. Clinicians should review patients ' OTC medications, said the researchers.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 4, 2022 Category: Primary Care Tags: Family Medicine/Primary Care News Source Type: news

Acetaminophen Label Changes Not Linked to Accidental OD Admission
TUESDAY, April 19, 2022 -- Modifications to labelling standards for acetaminophen, implemented in October 2009 and September 2016, were not associated with trends in hospital admission for accidental acetaminophen overdose, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2022 Category: Pharmaceuticals Source Type: news

Are you under treating pain in your ED?
Conclusion While I commend efforts to minimize any harm our therapies may have on patients, I remain unconvinced that using the maximum recommended dose of NSAIDs in the Emergency Department will have a net negative effect on them. In fact, given the systemic issue of oligoanalgesia in the ED, I’ll happily stick with 800 mg of ibuprofen, whether it be for my patients or myself. References: Motov S, Masoudi A, Drapkin J, et al. Comparison of Oral Ibuprofen at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2019;74(4):530-537. doi:10.1016/j.anne...
Source: EPMonthly.com - April 11, 2022 Category: Emergency Medicine Authors: Jeffrey Lyles Source Type: news

Palliative Care in Assisted Living
Mrs. M is a 92-year-old woman residing in an assisted living community. Her medical history includes hypertension, gout, hyperlipidemia, atrial fibrillation, hypothyroidism, and melanoma with invasion into the parotid gland; she has had removal of a lesion and a parotidectomy with nerve involvement impacting the 7th cranial nerve. Her medications include oral levothyroxine, 100 μg daily; oral vitamin D, 1,000 units daily; oral probenecid 500/colchicine, 0.5 mg daily; oral lisinopril, 5 mg daily; oral furosemide, 20 mg daily; oral duloxetine, 60 mg for depression; oral carvedilol, 6.25 mg twice a day; oral aspirin, 81 mg d...
Source: Caring for the Ages - March 29, 2022 Category: Health Management Authors: Barbara Resnick, Paige Hector Tags: Interdisciplinary Team Case Studies Source Type: news

Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension 2400 mg/30 mL, Magnesium Hydroxide 1200mg/Aluminum Hydroxide 1200mg/Simethicone 120mg per 30 mL, and Acetaminophen 650mg/ 20.3mL, Unit Dose Cups, Due to Microbial Contamination
Lawrence, KS, Plastikon Healthcare, LLC is voluntarily recalling three (3) lots of Milk of Magnesia 2400 mg/30 mL Oral Suspension, one (1) lot of Acetaminophen 650mg/ 20.3mL, and six (6) lots of Magnesium Hydroxide 1200mg/Aluminum Hydroxide 1200mg/Simethicone 120mg per 30 mL to the hospital, clinic (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 24, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news